CONCLUSION
Sirolimus has become a mainstay of treatment for patients with VAs, and many patients receiving sirolimus for VAs have also been reported to develop infectious complications. Although most infections were minor, one-third of reported infections were serious. However, reports of bacteremia and infectious fatalities are exceedingly rare, and only 1 episode of PJP has been reported in this patient population. In the future, multicenter studies should aim to further characterize the infectious complications of sirolimus for treatment of VAs. This future work will be essential to provide guidance to clinicians and families on how to best monitor and manage these patients.